RAINBOW Study: a Randomized, Controlled Study Evaluating the Efficacy and Safety of RAnibizumab Compared With Laser Therapy for the Treatment of INfants BOrn Prematurely With Retinopathy of Prematurity
Phase of Trial: Phase III
Latest Information Update: 11 Apr 2018
At a glance
- Drugs Ranibizumab (Primary)
- Indications Retinopathy of prematurity
- Focus Registrational; Therapeutic Use
- Acronyms RAINBOW
- Sponsors Novartis
- 26 Feb 2018 The trial has been completed in Czech Republic.
- 19 Jan 2018 Status changed from active, no longer recruiting to completed.
- 12 Jan 2018 This trial has been completed in Poland.